Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging

This study has been completed.
Sponsor:
Collaborator:
Genentech
Information provided by (Responsible Party):
Matthew MacCumber, Rush University Medical Center
ClinicalTrials.gov Identifier:
NCT00606138
First received: January 9, 2008
Last updated: May 25, 2012
Last verified: May 2012

January 9, 2008
May 25, 2012
January 2008
October 2010   (final data collection date for primary outcome measure)
  • The percentage change of the area of the patient's neovascularization as measured in pixels by Optomap FA [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: No ]
  • The percentage change of macular edema measured by retinal thickness by OCT [ Time Frame: Week 2, 4; Month 2, 3, 4, 6 ] [ Designated as safety issue: No ]
  • Incidence and severity of ocular adverse events, as identified by ophthalmic examination [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: Yes ]
  • Incidence and severity of other adverse events, as identified by physical examination, subject reporting, and changes in vital signs [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00606138 on ClinicalTrials.gov Archive Site
  • Mean change in Best Corrected Visual Acuity (BCVA), as assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: No ]
  • Percentage of patients gaining 3 or more lines of vision according to ETDRS eye chart testing [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: No ]
  • Occurrence rate of proliferative diabetic complications including vitreous hemorrhage, iris neovascularization, and tractional retinal detachment [ Time Frame: Week 1, 2, 4; Month 2, 3, 4, 5, 6 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Ranibizumab for Treatment of Persistent Diabetic Neovascularization Assessed by Wide-Field Imaging
Investigation of Ranibizumab for the Treatment of Persistent Diabetic Neovascularization as Assessed by Super Wide-Field Angiography (Optos)

The purpose is to compare the efficacy of ranibizumab versus additional panretinal photocoagulation on diabetic neovascularization that is persistent despite previous treatment with panretinal photocoagulation. We hypothesize that ranibizumab intravitreal injections would induce neovascular regression in similar or better fashion than supplemental laser photocoagulation. Consented, enrolled subjects will either receive open-label intravitreal injections of 0.5-mg dose of ranibizumab or additional panretinal photocoagulation (up to 500 300-500 um laser spots) in a ratio of two-to-one (2:1) at the beginning of the study period. ETDRS best-corrected visual acuity, contrast sensitivity, and Optos color photography will be performed at enrollment, at weeks 1, 2, 3 and 4, and at months 2, 3, 4, 5 and 6. The subjects will undergo fluorescein angiography utilizing the Optomap FA (fluorescein angiography) system and optical coherence tomography (OCT) at enrollment, at weeks 2 and 4, and at months 2, 3, 4 and 6. The subjects will be followed for a 6-month period for stabilization, regression, or recurrence of neovascularization. In addition, patients will be evaluated for occurrence of macular edema.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Proliferative Diabetic Retinopathy
  • Drug: ranibizumab
    One 0.5 mg intravitreal injection
    Other Name: Lucentis
  • Procedure: Laser photocoagulation
    panretinal photocoagulation (up to 500 300-500 um laser spots)
  • Experimental: 1
    Intravitreal injection of 0.5-mg dose of ranibizumab
    Intervention: Drug: ranibizumab
  • Active Comparator: 2
    Additional panretinal photocoagulation (up to 500 300-500 um laser spots)
    Intervention: Procedure: Laser photocoagulation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
10
October 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study
  • Age 18 years or older

Patient related considerations:

  • Patients with Diabetes Mellitus (Type I or II) are eligible. HgA1c will be evaluated at the beginning of the study, but this value will have no significance in inclusion or exclusion.
  • Patients will not be pregnant at enrollment and must provide evidence of the use of two types of birth control while enrolled in the study.
  • Patients will have no known sensitivity to ranibizumab or other anti-VEGF injections.

Disease related considerations:

  • Patients will have diabetic neovascularization as seen on fluorescein angiography that was previously treated with full (at least 1200 laser burns) panretinal photocoagulation and that has persisted at least three months.
  • There will be no evidence of ocular inflammation at enrollment.
  • There is no restriction on patient's current medications or concomitant illnesses as long as there is no interference with patient follow-up.

Other considerations:

  • Patients may not be enrolled in another clinical study or observational trial.
  • There is no limitation on patient's institutional status as long as the patient is able to participate in follow-up.

Exclusion Criteria:

  • Pregnancy (positive pregnancy test)
  • Uncontrolled glaucoma on three medicines or more to control intraocular pressure
  • Prior enrollment in the study
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated
  • Participation in another simultaneous medical investigation or trial
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00606138
06120402
No
Matthew MacCumber, Rush University Medical Center
Rush University Medical Center
Genentech
Principal Investigator: Mathew W MacCumber, MD, PhD Rush University Medical Center
Rush University Medical Center
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP